BRAF Inhibitor-Induced Panniculitis: Appearance on 18F-FDG PET/CT. (March 2016)

• Record Type: Journal Article
• Authors: Broski, Stephen M.; Moran, Erin K.; Glazebrook, Katrina N.; Nathan, Mark A.
• Is Part Of: Clinical nuclear medicine. Volume 41:Number 3(2016)
• Publication Date: 2016-03
• Subjects: panniculitis -- FDG -- PET/CT -- BRAF; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000001027
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract : Abstract: BRAF inhibitors vemurafenib and dabrafenib have become the standard of care for treatment of stage IV metastatic melanoma harboring a BRAF mutation. Panniculitis is a rare but known adverse side effect of these agents and presents with tender erythematous nodules. These nodules may demonstrate uptake on 18 F-FDG PET/CT, which may mimic metastatic disease in patients undergoing treatment. We present a case of BRAF inhibitor-induced panniculitis in a patient with stage IV metastatic melanoma and discuss the imaging findings on 18 F-FDG PET/CT.